← All organizations
First clinical trial
May 1, 2000First marketed drug
Jun 5, 1947First NDA
Mar 22, 1950Last known activity
Feb 21, 2008
Acquired by Pfizer on Oct 15, 2009
Timeline
1920s
- Jan 1, 1926
American Home Products— Founded
1930s
- Jan 1, 1931
Wyeth— Acquired
1940s
- Jan 1, 1943
Ayerst, McKenna and Harrison— Acquired
1960s
- Apr 30, 1965
ethionamide— NDA Organization
1970s
- Aug 29, 1975
lidocaine— Marketing Organization
1980s
- Dec 12, 1980
isosorbide— NDA Secondary Org
- Jan 1, 1982
Sherwood Medical— Acquired
- Jan 1, 1988
AH Robins— Acquired
1990s
- Jan 1, 1994
American Cyanamid— Acquired
- Jan 1, 1996
Genetics Institute— Acquired
- May 11, 1998
Apollon— Acquired
2000s
- Dec 19, 2008
Thiakis Ltd— Acquired
- Oct 15, 2009
Pfizer— Acquired By
Drugs by trial phase (204 distinct, 539 trials)
Phase 4 (0 own, 46 via acquisition)
- venlafaxine
- etanercept
- piperacillin
- sirolimus
- citalopram
- pneumococcal 7-valent conjugate vaccine
- leflunomide
- antihemophilic factor viii (Recombinant)
- cyclosporine
- antihemophilic factor viii human
- tacrolimus
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- duloxetine
- gemtuzumab ozogamicin
- tigecycline
- +31 more
Phase 3 (0 own, 54 via acquisition)
Phase 2 (0 own, 36 via acquisition)
Phase 1 (0 own, 54 via acquisition)
Indications
Approved for
- Acute Pain
- Alcohol Abstinence
- Angina Pectoris
- Anxiety Disorders
- Arrhythmias, Cardiac
- Arthritis, Infectious
- Arthritis, Rheumatoid
- Attention Deficit Disorder with Hyperactivity
- Bacterial Infections
- Carcinoma, Renal Cell
- Cardiomyopathy, Hypertrophic, Familial
- Coronary Artery Disease
- Depressive Disorder
- Dysmenorrhea
- Endocarditis
- Endocarditis, Bacterial
- Esophagitis
- Fertilization
- Gastroesophageal Reflux
- Glaucoma
- Gram-Negative Bacterial Infections
- Heart Failure
- Hypertension
- Hypotension
- Infections
- Lymphangioleiomyomatosis
- Major Depressive Disorder
- Meningitis, Bacterial
- Menorrhagia
- Migraine Disorders
- Obesity
- Ocular Hypertension
- Osteoarthritis
- Osteomyelitis
- Otitis Media
- Pain
- Peptic Ulcer
- Phobia, Social
- Pneumococcal Infections
- Pregnancy
- Pulmonary Disease, Chronic Obstructive
- Respiratory Tract Infections
- Sepsis
- Sialorrhea
- Skin Diseases, Infectious
- Sleep Disorders, Intrinsic
- Sleep Initiation and Maintenance Disorders
- Spasm
- Staphylococcal Infections
- Streptococcal Infections
- Tachycardia, Ventricular
- Tuberculosis
- Urinary Tract Infections
- Zollinger-Ellison Syndrome
Marketed drugs (95)
Subsidiaries (8 direct, 12 total across the full acquisition tree)
Recent trials (1)
- NCT00681213CollaboratorPhase 4May 1, 2000
Details
- Founded
- Philadelphia, PA, US Jan 1, 1926
- First NDA
- Mar 22, 1950
- Last known activity
- Feb 21, 2008
Designations held
- Orphan drug
- Priority review
- Accelerated approval